Pharmacokinetics,Safety and Efficacy of Saquinavir/ Ritonavir 1,000/100 Mg Twice Daily as HIV Type-1 Therapy and Transmission Prophylaxis in Pregnancy

Abstract

Background

A saquinavir/ritonavir-containing regimen is one option for the prevention of mother-to-child transmission of HIV during pregnancy. We evaluated the pharmaco-kinetics, efficacy and safety of saquinavir/ritonavir 1,000/100 mg twice daily plus nucleos(t)ide reverse transcriptase inhibitors in 13 women during late pregnancy and compared the results to those of 15 non-pregnant women.

Methods

Protease inhibitor plasma concentration profiles were assessed at 12 h using a standardized therapeutic drug monitoring procedure and measured by LC-MS/MS. Minimum and maximum concentrations (C_min and C_max), area under the plasma concentration–time curve (AUC_0–12 _h), and total clearance (CL _total) were compared between the groups and correlated to demographic, physiological and clinical cofactors. Antiviral and immunological efficacy and safety were investigated.

Results

The geometric means (90% confidence interval [CI]) for saquinavir C_min, C_max and AUC_0–12 _h of pregnant versus non-pregnant women were 572 (437–717) versus 765 (485–1,052, P=0.064) ng/ml, 2,168 (1,594–2,807) versus 3,344 (2,429–4,350; P=0.045) ng/ml and 15,512 (11,657–19,943) versus 24,027 (17,454–31,548, P=0.029) ng•h/ml. The geometric means (90% CI) for ritonavir C_min, C_max and AUC_0–12 _h were 190 (148–234) versus 310 (240–381, P=0.011) ng/ml, 781 (580–999) versus 1,552 (1,127–2,007, P=0.004) ng/ml and 5,576 (4,303–7,006) versus 10,528 (8,131–13,177, P=0.003) ng•h/ml. Age, weight, saquinavir dose per weight and body mass index differed significantly; saquinavir C_min and AUC_0–12 _h were correlated with ritonavir C_min and saquinavir dose per weight. After a mean of 11 weeks treatment, 12 of 13 pregnant women had a viral load <400 copies/ml, which was similar to the results of non-pregnant women.

Conclusions

Although saquinavir plasma concentrations were significantly lower in pregnant women compared with non-pregnant women, all pregnant women displayed a saquinavir AUC_0–12 _h>10,000 ng•h/ml, 92.3% had a viral load <400 copies/ml at birth. Saquinavir was well tolerated by the mothers and all newborn children were HIV type-1 negative at 18 months of age.

References

Department for Health and Human Services (US). Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. (Updated 8 July 2008. Accessed 24 July 2008.) Available from http://www.aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.

Department of Health and Human Services (US). Safety and toxicity of individual antiretroviral agents in pregnancy. (Updated 6 July 2006. Accessed September 2006.) Available from www.aidsinfo.nih.gov.

Robert Koch Institut, Deutsche AIDS-Gesellschaft (DAIG), Österreichische AIDS-Gesellschaft (ÖAG). DeutschÖsterreichische Empfehlungen zur HIV-Therapie in der Schwangerschaft. 2003 (Updated 24 September 2008. Accessed 30 November 2008.) Available from www.rki.de/cln_091nn_753398/DE/Content/InFAZ/H/HIVAIDS/Therapie/Leitlinien/PDF_D_A.

Penzak

S.R.

, Acosta

E.P.

, Turner

, Tavel

J.A.

, Masur

Analysis of generic nevirapine products in developing countries. JAMA 2003; 289: 2648–2649.

Mirochnick

, Fenton

, Gagnier

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178: 368–374.

Mirochnick

, Siminski

, Fenton

, Lugo

, Sullivan

J.L.

Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001; 20: 803–805.

Phanuphak

, Apornpong

, Teeratakulpisarn

Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med 2007; 8: 357–366.

Jamisse

, Balkus

, Hitti

Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007; 44: 371–376.

Marazzi

M.C.

, Germano

, Liotta

Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med 2006; 7: 338–344.

10.

Lyons

, Hopkins

, Kelleher

Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7: 255–260.

11.

McIntyre

J.A.

Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV. Expert Opin Pharmacother 2006; 7: 677–685.

12.

von Hentig

, Carlebach

, Gute

A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol 2006; 62: 552–559.

13.

Vithayasai

, Moyle

G.J.

, Supajatura

Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission. J Acquir Immune Defic Syndr 2002; 30: 410–412.

14.

Acosta

E.P.

, Zorrilla

, Van Dyke

Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2001; 2: 460–465.

15.

Acosta

, Bardeguez

, Zorrilla

C.D.

Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chaemother 2004; 48: 430–436.

16.

Lopez-Cortes

L.F.

, Ruiz-Valderas

, Pascual

, Rodriguez

, Marin Niebla

Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy. HIV Clin Trials 2003; 4: 227–229.

17.

Lopez-Cortes

L.F.

, Ruiz-Valderas

, Rivero

Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit 2007; 29: 171–176.

18.

Invirase (saquinavir mesylate). Invirase Product Information revised December 2003. Roche Laboratories Inc.

Nutley, NJ, USA.

19.

Invirase (saquinavir mesylate). Invirase Dear Doctor Letter issued May 2005. Roche Laboratories Inc.

Nutley, NJ, USA.

20.

Burger

, Eggink

, van der Ende

The pharmacokinetics of saquinavir new tablet formulation + ritonavir (1000/100 mg twice daily) in HIV-1 infected pregnant women. 14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2007, Los Angeles, CA, USA. Abstract 741.

21.

Tung

, Boffito

, Taylor

Pharmacokinetics (PK), safety, tolerability and efficacy of boosted saquianvir 500 mg film coated tablets in a regimen of 1000/100 mg twice daily plus 2 nucleoside analogues (NRTIs) in HIV+ pregnant women. 8th International Congress on Drug Therapy in HIV Infection. 12–16 November 2006, Glasgow, UK. Abstract P383.

22.

van der Lugt

The influence of pregnancy on the pharmacokinetics of saquinavir boosted by low-dose ritonavir (1000/100 mg twice daily). 9th International Workshop on Clinical Pharmacology of HIV Therapy. 7–9 April 2008, New Orleans, LA, USA. Abstract 9.

23.

Stephan

, von Hentig

, Kourbeti

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004; 18: 503–508.

24.

Maserati

, Villani

, Cocchi

, Regazzi

Co-trimoxazole administered for Pneumocystis carinii pneumonia prophylaxis does not interfere with saquinavir pharmacokinetics. AIDS 1998; 12: 815–816.

25.

KKGT. International Interlaboratory Quality Control Program for therapeutic drug monitoring in HIV infection 2006. University of Nijmwege the Netherlands. (Updated 30 September 2008. Accessed October 2008.) Available from http://kkgt.nl.

26.

Kurowski

, Sternfeld

, Sawyer

, Hill

, Mocklinghoff

Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med 2003; 4: 94–100.

27.

Boffito

, Kurowski

, Kruse

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir boosted once-daily regimen. AIDS 2004; 18: 1291–1297.

28.

Heinzel

, (Editor). TOPFIT 2.0 Pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuttgart: Gustav Fischer Verlag 1993.

29.

AIDS Clinical Trials Group. Toxicity tables 2004. (Updated 9 August 2006. Accessed November 2008.) Available from http://rcc.tech-res.com/tox_tables.htm.

30.

NIH. Common terminology criteria for adverse events (formerly CTC) V3.0. 2003 (Updated December 2004. Accessed November 2008.) Available from http://ctep.info.nih.gov/forms/CTCAEv3.pdf.

31.

Zorrilla

C.D.

, Van Dyke

, Bardeguez

Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrob Agents Chaemother 2007; 51: 2208–2210.

32.

Kosel

B.W.

, Beckerman

, Hayashi

, Homma

, Aweeka

Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17: 1195–1199.

33.

Gingelmaier

, Kurowski

, Kastner

Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006; 20: 1737–1743.

34.

Mirochnick

, Capparelli

Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43: 1071–1087.

35.

Stek

A.M.

, Mirochnick

, Capparelli

Reduced lopinavir exposure during pregnancy. AIDS 2006; 20: 1931–1939.

36.

Marzolini

, Kim

R.B.

Placental transfer of antiretroviral drugs. Clin Pharmacol Ther 2005; 78: 118–122.

37.

Mirochnick

, Dorenbaum

, Holland

Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002; 21: 835–838.

38.

Gimenez

, Fernandez

, Mabondzo

Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J Acquir Immune Defic Syndr 2004; 36: 649–658.

39.

Nettles

R.E.

, Kieffer

T.L.

, Parsons

Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42: 1189–1196.

40.

von Hentig

, Babacan

, Staszewski

, Sturmer

, Doerr

H.W.

, Lotsch

Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients. Antivir Ther 2007; 12: 1237–1246.